Abstract
Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Current Pharmaceutical Design
Title: The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Volume: 15 Issue: 1
Author(s): Christine L. Miller
Affiliation:
Keywords: Nicotinic acid, tuberculosis, schizophrenia, evolution
Abstract: Schizophrenia is a common, debilitating mental illness that has persisted over the generations. For a disease with a strong genetic component, such prevalence has been difficult to understand in evolutionary terms. A model for its prevalence as a phenotype is presented in this manuscript, based on reports of specific differences in gene expression, metabolite levels and historical epidemiology. The selective force that underlies the proposed model is tuberculosis, a scourge of huge proportions that itself evolved to interact with the human host in a manner ensuring both its long term persistence in the host and its transfer to other carriers prior to the hosts unfortunate death. The focal point of the interaction between humans and M. tuberculosis is hypothesized to be the de novo synthesis of NAD via activation of the kynurenine pathway. The strategy that M. tuberculosis employed to circumvent this aspect of the hosts response to mycobacterial infection, and how that strategy interacted with a poor diet to force human evolution towards increased risk for schizophrenia, forms the basic premise of this paper. The model has implications for treatment of both diseases and generates hypotheses to be tested.
Export Options
About this article
Cite this article as:
Miller L. Christine, The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD, Current Pharmaceutical Design 2009; 15(1) . https://dx.doi.org/10.2174/138161209787185805
DOI https://dx.doi.org/10.2174/138161209787185805 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Protein Peptide Informatics and Drug Designing - Some Computational Techniques for Structural Genomics Based Approaches (Part II) (Guest Editor: Rajani R. Joshi)]
Protein & Peptide Letters Patent Selections
Recent Patents on Anti-Infective Drug Discovery Update on the Management of Spondyloarthritis in Asian Countries
Current Rheumatology Reviews QSAR Studies on NTF1836 Analogues as Mycothiol Biosynthesis Inhibitors
Letters in Drug Design & Discovery Computational Biology and Drug Discovery: From Single-Target to Network Drugs
Current Bioinformatics Developing Solid Particulate Vaccine Adjuvants: Surface Bound Antigen Favours a Humoural Response, whereas Entrapped Antigen Shows a Tendency for Cell Mediated Immunity
Current Drug Delivery Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Editorial [Hot Topic:Protein targets for development of drugs against Mycobacterium tuberculosis (Guest Editor: Walter Filgueira de Azevedo)]
Current Medicinal Chemistry Principles and Practices of Pathway Modelling
Current Bioinformatics Micronutrient Deficiency in Pulmonary Tuberculosis - Perspective on Hepatic Drug Metabolism and Pharmacokinetic Variability of First-line Anti- Tuberculosis Drugs: Special Reference to Fat-soluble Vitamins A, D, & E and Nutri-epigenetics
Drug Metabolism Letters Mechanistic Approach to Explore Isoniazid Derivatives as Antitubercular Agents Using KNN-MF Based-QSAR Analysis, Pharmacophore Modeling and Molecular Docking
Current Drug Therapy Detection of the Incidence of Infections and Acute Biochemical Changes in Diffused Large B-Cell Lymphoma Patients Treated with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) with and without Rituximab
Current Drug Safety A Novel Feature-Significance Based k-Nearest Neighbour Classification Approach for Computer Aided Diagnosis of Lung Disorders
Current Medical Imaging The Role of Bacterial Lipopolysaccharides as Immune Modulator in Vaccine and Drug Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Expression of Toll-like Receptor 2 and Toll-like Receptor 4 in Tuberculous Pleural Effusion
Medicinal Chemistry Lipids as Activators of Innate Immunity in Peptide Vaccine Delivery
Current Medicinal Chemistry Evaluation of the Agreement Between the Tissue Sample and Bronchoalveolar Lavage (BAL) Fluid in the Diagnosis of Tuberculosis in Patients with Anthracosis
Current Respiratory Medicine Reviews An Update of the Published Reports on Biologics Use for Psoriasis and the Reimbursement Status in Asia-Pacific Region
Current Rheumatology Reviews Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation
Protein & Peptide Letters